50 results about "Medication adherence" patented technology

A system and method for generating patient care instructions based on real-time sensor and medical data. The method includes receiving time-stamped sensor data from a sensor network comprising motion, occupancy, and environmental sensors, and receiving medical data associated with a patient, including medical conditions, treatment history, medication data, and biometric data. The sensor data is enriched with room-specific information, and activity pattern data is generated in real time using a pattern recognition model. The activity pattern data includes mobility, sleep patterns, medication adherence, statistical measures, temporal patterns, and correlations with medical data. Anomalies indicating potential health risks are detected by comparing current activity patterns with baseline data. A prediction model, trained on historical patient data, assesses the patient's health and generates care instructions accordingly. The care instructions are securely delivered to patient devices, caregiver applications, or automated medication dispensing systems, enabling timely interventions and continuous patient monitoring.

Systems, devices, and methods described herein indirectly monitor a state of fluid flow by monitoring a state of connection of a medication delivery device. The system includes an enclosure, a contact sensor, and a controller. The enclosure can attach around at least a portion of an outer surface of the medication delivery device to enclose at least a portion of the outer surface therein. The contact sensor and controller are enclosed within the enclosure. The contact sensor can monitor a state of electrical connection. The controller is in communication with the contact sensor and can relay the state of electrical connection. The state of connection of the contact sensor corresponds to the state of connection of the medication delivery device.

A method of supporting user adherence to a medication regimen includes storing received medication information associated with one or more medications using a patient wearable device and a coordinated care platform. The method also includes displaying identification and dosing information associated with the medications, generating a notification indicating that the identification information is being displayed, monitoring a response input indicating that the medications have been administered. For each of the one or more medications displayed, the method includes generating a medication status describing that either (i) the medication has been administered or (ii) the response has not been received. The method further includes generating a reminder notification when the medication status indicates that the response has not been received. The method may further include gathering behavioral data points associated with the user for submission to the coordinated care platform, which performs predictive analytics based on the data points.

A medication adherence system and device are disclosed including a medicine dispensing cup having a sensor portion including a processor, memory, power supply, network adaptor therein, and a camera, the camera directed upwardly and positioned at the top of the sensor portion. In various embodiments a medicine containment portion to hold consumable medicine placed within is attachable with the sensor portion and may include a transparent portion on its bottom. When attached, the transparent portion is aligned with the camera such that the camera views upwardly through the bottom where the camera is configured to capture medication adherence data indicating whether medicine within the attached medicine containment portion has been consumed. The medicine dispensing cup may be received in a base unit that may provide charging of the power supply and further complementary medication adherence data. Data received from or derived from the camera may be provided to EMR systems.

The present invention can provide: a colon purgation tablet having a gel-forming coating layer containing an alginate as a main component, the gel-forming coating layer being introduced into an uncoated tablet containing an osmotic substance, the present invention relates to an uncoated tablet, and more particularly, to an uncoated tablet, such that the osmotic substance contained in the uncoated tablet disintegrates rapidly while preventing damage to gastric mucosa due to a physical collision between the tablet and the gastric mucosa, and thus provides an excellent intestinal cleansing effect. The colon purgation tablet according to the present invention can exhibit an excellent intestinal cleansing effect even at a small dose, and can further improve drug compliance by selectively miniaturizing the tablet or introducing an adhesive to improve a coating layer.

Most therapeutic treatments require dose adjustment after initial administration. Dosage adjustment is crucial to ensuring optimal safety and efficacy characteristics of the treatment. Gene therapy is inherently limited by the inability to adjust the dose after initial administration. This invention describes a genetic element capable of dose adjustment after the initial administration of gene therapy. The realization of dose adjustment allows for the replacement of multiple subcutaneous protein injection regimens with single-injection gene therapy, thereby improving pharmacokinetics, safety / efficacy characteristics, medication adherence, and reducing healthcare costs.

Disclosed herein is a medication and health management system and method for assisting a caregiver to monitor medication adherence of a care recipient. An example system comprises a first computing device configured to store medications of a care recipient in a plurality of chambers, monitor the care recipient's adherence to a medication schedule via at least one sensor, and transmit measurement data of the at least one sensor to a computing server system. The computing server system is configured to process the received measurement data to determine whether any chamber has been opened for retrieval of the medications stored therein in accordance with the medication schedule of the care recipient, in response to determining that no chamber has not been opened, generate and transmit a notification signal to a second computing device of a caregiver of the care recipient to indicate a medication non-adherence event of the care recipient.

The present invention provides an injectable depot composition comprising enavogliflozin and a low-dose liraglutide. A combination regimen of enavogliflozin and a low-dose liraglutide provides a synergistic effect in the treatment of obesity compared to the sole administration of either of the drugs. In addition, compared to the sole administration of liraglutide, the administered dose of liraglutide can be reduced, and thus direct causes of gastrointestinal and cardiovascular side effects of liraglutide can be mitigated. In addition, the present invention has the advantage of additionally providing the effect of alleviating metabolic diseases and cardiovascular diseases related to blood glucose, blood lipids, blood pressure, fatty liver, and the like through combined administration with enavogliflozin. Furthermore, the depot composition of enavogliflozin and liraglutide according to the present invention can significantly improve medication convenience and medication adherence for a patient compared to existing liraglutide formulations, which are subcutaneously injected once a day, by unifying the route of administration and improving the administration cycle.

An automatic medication intake and dispensing system is disclosed. The system enhances medication adherence and facilitates health monitoring by employing NFC-tagged medication bottles that communicate prescription data to an integrated NFC reader. A mechanical arm transfers medication into a rotational storage tray with designated compartments. At scheduled times, the system automatically retrieves the appropriate medication using a vacuum-assisted mechanism and delivers it to the user. If a dose is missed, the system initiates retry and alert protocols. Integrated telehealth capabilities include video and audio transmission, along with vital sign monitoring modules for measuring blood pressure, heart rate, and blood oxygen levels. A temperature sensor is also incorporated. A single-board computer manages system operations and uploads data, including missed doses and health metrics, to a secure cloud platform for access by patients, caregivers, and healthcare providers. The system provides secure prescription management, automated dispensing, and continuous health data collection.

This invention proposes an intelligent menopausal patient health management platform, comprising a doctor-patient interaction unit, an information processing unit, a pharmaceutical service unit, and a medical terminal. The doctor-patient interaction unit allows patients to conveniently fill in initial diagnosis information, including questionnaire data and medication information, on a mobile terminal, achieving effective collection of information from outside the hospital. The information processing unit can perform structured processing of this information. Based on risk assessment results and medication information, the pharmaceutical service unit can intelligently generate a pharmaceutical service plan including medication rescheduling suggestions, individualized medication guidance, and follow-up reminders. This not only improves the accuracy and safety of medication use but also enhances patient medication adherence through continuous follow-up reminders. The medical terminal provides medical staff with an integrated view of patient information, enabling them to comprehensively understand the patient's initial diagnosis information, system-generated risk assessment results, and pharmaceutical recommendations, and efficiently respond to complex patient questions.

A wearable device for wearing by a patient in receipt of medication, comprising components of a medication and patient monitoring unit (MPMU) including: an interactive visual display unit (VDU), an interactive audio platform (AP) and a plurality of sensor units (SUs); and comprising components of an operating unit (OU) including: a processing unit (CPU) and memory, a wireless communication unit (WCU), a power supply unit (PSU) and an energy storage unit (ESU) wherein a plurality of sensor units comprises at least one dehydration sensor unit (DHSU).

A nebulizer monitoring system and a medication adherence monitoring method. The nebulizer monitoring system includes a nebulizer and a remote monitoring platform. The nebulizer has a mouthpiece. The nebulizer includes a nebulizing module, a sensing assembly, and a control module. The control module is electrically connected to the nebulizing module and the sensing assembly. The remote monitoring platform includes a computing module. The computing module is configured to analyze and calculate at least two adherence parameters and generate a breathing pattern. The control module is configured to adjust a nebulizing frequency and an aerosol volume of the nebulizing module based on the breathing pattern.

This invention discloses a multimodal health management method and system for TIPS postoperative care, specifically relating to the field of medical and health management technology. It involves constructing a postoperative multimodal follow-up dataset by collecting patient health consultation records, dietary protein intake records, oral medication adherence records, and doctor-patient feedback records. Through consultation topic classification, protein intake deviation identification, medication adherence breakpoint detection, and feedback tendency determination, a set of behavioral events is extracted. Within the same follow-up period, co-occurrence associations of consultation, diet, medication, and feedback events are established to generate a risk trigger chain for hepatic encephalopathy. Based on the risk trigger chain, the intervention type is determined, generating individualized intervention instructions such as dietary guidance, medication reminders, and health consultation responses. These intervention instructions are then pushed to both the patient and healthcare professionals, collecting execution and treatment feedback and writing it back into the dataset to form a closed-loop follow-up update. Finally, the updated data is used to correct the risk trigger chain and automatically generate intervention instructions for the next cycle.

A medication adherence and monitoring system and method for use with pill packet dosing is provided. The system is configured to mount on a medication reservoir that stores a stream of pill packets. The system utilizes a processor in conjunction with an optical scanner, to read scannable codes on the stream of pill packets to configure the system and track extraction of the pill packets from the reservoir when they pass by the optical scanner as the pill packets are extracted from the reservoir through an opening in a housing that spans or covers a storage container for the pill packets. The system further provides prompting and feedback for the extraction of the pill packets while monitoring compliance with the dosage schedule for the user.

This invention discloses a method for medication risk warning and dynamic intervention using a smart pillbox for elderly patients with chronic diseases, relating to the fields of intelligent medical devices and chronic disease management technology. The method first constructs four types of chronic disease knowledge graphs: medication behavior, physiological indicators, drug interactions, and environmental conditions. Then, it processes the graphs using a GNN module with a GRU-like gating mechanism, weightedly fusing multi-time-step features using a time-step attention mechanism, and integrating similar patient features based on Jaccard similarity to generate comprehensive risk features. During the training phase, the risk level and type are output after feature optimization using a collaborative attention mechanism. In the inference phase, a similarity propagation mechanism is used to address the cold-start problem for newly enrolled patients, matching a three-level intervention rule base to generate personalized strategies, and iteratively optimizing the model based on intervention feedback. This invention achieves proactive and precise warning and dynamic intervention, improving risk assessment performance and patient medication adherence in different scenarios.

A medication adherence and monitoring system and method for use with pill packet dosing is provided. The system is configured to mount on a medication reservoir that stores a stream of pill packets. The system utilizes a processor in conjunction with an optical scanner, to read scannable codes on the stream of pill packets to configure the system and track extraction of the pill packets from the reservoir when they pass by the optical scanner as the pill packets are extracted from the reservoir through an opening in a housing that spans or covers a storage container for the pill packets. The system further provides prompting and feedback for the extraction of the pill packets while monitoring compliance with the dosage schedule for the user.

A medication adherence and monitoring system and method for use with pill packet dosing is provided. The system is configured to mount on a medication reservoir that stores a stream of pill packets. The system utilizes a processor in conjunction with an optical scanner, to read scannable codes on the stream of pill packets to configure the system and track extraction of the pill packets from the reservoir when they pass by the optical scanner as the pill packets are extracted from the reservoir through an opening in a housing that spans or covers a storage container for the pill packets. The system further provides prompting and feedback for the extraction of the pill packets while monitoring compliance with the dosage schedule for the user.

This invention belongs to the field of pharmaceutical technology, specifically relating to a method for preparing mabaloxavir tablets and its application. This invention uses lactose dodecyl ester and microcrystalline cellulose to microcrystallize mabaloxavir, reducing its particle size and increasing its specific surface area, thereby accelerating the drug's dissolution rate in vivo, improving its bioavailability, allowing the drug to exert its effects more quickly, and shortening the patient's treatment cycle. The use of lactose dodecyl ester, microcrystalline cellulose, croscarmellose sodium, and povidone K25 as excipients helps form a uniform and stable carrier solution and mixture, and also improves the tablet's formability, disintegration, and dissolution properties during tableting, improving tablet quality and stability, reducing gastrointestinal irritation, and enhancing patient medication adherence.

This invention discloses a maltol-ferric oxalate cocrystal, which is formed using maltol-ferric as the active pharmaceutical ingredient and oxalate as the cocrystal ligand via a suspension stirring method. In the X-ray powder diffraction pattern obtained using Cu-Kα radiation, the maltol-ferric oxalate cocrystal exhibits characteristic diffraction peaks at diffraction angles 2θ of approximately 14.7±0.2°, 17.0±0.2°, 17.6±0.2°, 24.8±0.2°, 26.6±0.2°, and 26.9±0.2°. The maltol-ferric oxalate cocrystal of this invention exhibits good stability, showing no crystal transformation for at least 60 days under accelerated conditions. Compared to maltol-ferric, the maltol-ferric oxalate cocrystal has relatively lower solubility in water. Low-solubility cocrystals typically dissolve more slowly, avoiding rapid drug concentration peaks, reducing the toxic side effects of maltol-ferric, and improving medication adherence.

This invention provides a heterocyclic compound, its preparation method, and its use in preparing GLP-1 receptor agonist prodrugs with oral and long-acting pharmacokinetic properties, belonging to the field of medicinal chemistry. The compound provided by this invention can be used as a GLP-1 receptor agonist prodrug, which can release a parent drug with GLP-1 receptor agonist activity through hydrolysis in vivo. The compound provided by this invention can be used as a GLP-1 receptor agonist prodrug compound for the preparation of drugs for the prevention and / or treatment of GLP-1 receptor-related diseases. The compound of this invention exhibits good oral and long-acting pharmacokinetics, resulting in better medication adherence and broad application prospects.

This invention discloses an IoT-based intelligent monitoring and medication reminder system for military personnel with chronic diseases, relating to IoT medical technology and military medical and health technology. It includes a terminal monitoring module, an intelligent medication reminder module, a cloud data processing platform, and a medical collaboration module. The terminal monitoring module collects physiological indicator data and medication-related status data from military patients with chronic diseases. The intelligent medication reminder module, through scene recognition and dynamic adjustment mechanisms, perfectly adapts to military training tasks. Relying on motion sensors to identify training scenarios, it automatically switches to a low-interference reminder mode of vibration + text, avoiding auditory warnings from interfering with training. Simultaneously, it dynamically adjusts the priority of medication reminders according to training intensity, delaying reminders for non-urgent medications until training breaks to ensure no reminders are missed or disruptive. Combined with a three-level early warning mechanism, it improves medication adherence and solves the problems of traditional reminder methods being singular and easily interfered with during training.

This invention provides a method for preparing natural nanophases of a Uyghur medicine compound preparation for treating eczema and its application. Based on a patent (CN201911308259.1) for a compound preparation for treating skin inflammation, this method regulates the solvent composition, concentration conditions, and mixing method of the extraction system to form a stable multiphase structure. Further, differential centrifugation is used to achieve directional separation of phases with different particle sizes, thereby obtaining natural nanophases. The obtained natural nanophases enrich the active ingredients in the compound preparation, significantly reduce cytotoxicity, and enhance biocompatibility. Simultaneously, they significantly inhibit NO production and exhibit eczema-related antibacterial activity, improving drug absorption and utilization efficiency, thus demonstrating superior eczema-related biological activity. This method also addresses the issue of the darker color of the product obtained from the original preparation process, improving the acceptability of the preparation and medication adherence.

A system and method for generating patient care instructions based on real-time sensor and medical data. The method includes receiving time-stamped sensor data from a sensor network comprising motion, occupancy, and environmental sensors, and receiving medical data associated with a patient, including medical conditions, treatment history, medication data, and biometric data. The sensor data is enriched with room-specific information, and activity pattern data is generated in real time using a pattern recognition model. The activity pattern data includes mobility, sleep patterns, medication adherence, statistical measures, temporal patterns, and correlations with medical data. Anomalies indicating potential health risks are detected by comparing current activity patterns with baseline data. A prediction model, trained on historical patient data, assesses the patient's health and generates care instructions accordingly. The care instructions are securely delivered to patient devices, caregiver applications, or automated medication dispensing systems, enabling timely interventions and continuous patient monitoring.

This invention discloses the application of a pharmaceutical composition containing curculigoside in the treatment of type 2 diabetic nephropathy, belonging to the technical field of diabetic nephropathy drugs. The pharmaceutical composition uses curculigoside and astragaloside A as active ingredients, and also includes pharmaceutically acceptable excipients, wherein the mass ratio of curculigoside to astragaloside A is 1:0.2 to 1:1.5. This invention is the first to apply curculigoside to the treatment of type 2 diabetic nephropathy. Through the synergistic effect of curculigoside and astragaloside A, it can significantly improve renal function in patients with type 2 diabetic nephropathy, inhibit inflammatory responses and oxidative stress, reduce renal pathological damage, and delay the progression of renal fibrosis. Furthermore, the pharmaceutical composition has high safety, no obvious adverse reactions, diverse dosage forms, and high medication adherence, overcoming the shortcomings of existing therapeutic drugs with limited efficacy and numerous adverse reactions, and has significant clinical value and broad application prospects.

A content management system for injectable medication administration provides personalized educational content and behavioral incentives based on user demographics and medication needs. The system includes modules for targeting relevant content and incentives based on behavioral patterns, analyzing engagement metrics, and generating performance reports. An authorization module controls content distribution and enables dynamic copay adjustments based on compliance. The system incorporates gamification elements, behavioral economics-based incentives, and points-based rewards to encourage medication adherence. Analytics capabilities track user engagement, monitor behavioral responses, and measure program effectiveness while maintaining compliance-based reward tracking.

An automatic medication intake and dispensing system is disclosed. The system enhances medication adherence and facilitates health monitoring by employing NFC-tagged medication bottles that communicate prescription data to an integrated NFC reader. A mechanical arm transfers medication into a rotational storage tray with designated compartments. At scheduled times, the system automatically retrieves the appropriate medication using a vacuum-assisted mechanism and delivers it to the user. If a dose is missed, the system initiates retry and alert protocols. Integrated telehealth capabilities include video and audio transmission, along with vital sign monitoring modules for measuring blood pressure, heart rate, and blood oxygen levels. A temperature sensor is also incorporated. A single-board computer manages system operations and uploads data, including missed doses and health metrics, to a secure cloud platform for access by patients, caregivers, and healthcare providers. The system provides secure prescription management, automated dispensing, and continuous health data collection.

This invention relates to the field of intelligent medical information technology, providing an information-based planning system for acne patients based on the IMB model. The system collects facial acne characteristics, medication adherence, and facial oil characteristics data from acne patients. It constructs a gridded oil-matching medication adherence index and a gridded acne condition index. Through oil secretion gradient weighted fusion and dynamic condition calibration, it outputs the facial gridded drug utilization rate results. Furthermore, it identifies the influencing factors of each facial grid and performs spatial aggregation to generate medication adherence planning instructions that match the individual's facial region characteristics. This invention forms a closed-loop process from condition gridded perception, multi-dimensional behavior quantification, drug utilization rate attribution assessment to regional targeted intervention. It achieves refined and intelligent acne medication management based on differences in facial oil secretion and lesion aggregation characteristics, significantly improving the accuracy of individualized intervention for acne patients' topical medication behavior.

A medication system for dispensing prescription medications. The medication system has a software application adapted to provide access to a plurality of modular containers secured by a locking mechanism. The software application is adapted to collect data regarding individuals receiving care to automate documentation for regulatory compliance. The software application can also provide guided medication adherence instructions.

The application discloses a kind of for managing the drug management system and method of tracking patient drug remaining amount, belong to medical information technology field.The system includes center server, doctor terminal, pharmacy terminal, inventory calculation and tracking engine, intelligent early warning module and patient terminal.Its core is through inventory calculation and tracking engine, according to the medication regimen in electronic prescription, and combining with the medication data fed back by patient, the real-time estimated remaining amount of drug is dynamically calculated.Intelligent early warning module monitors the remaining amount and the estimated remaining days, medication adherence rate and other indicators derived therefrom, and automatically triggers graded early warning when preset conditions are met.The application realizes the precise, automatic tracking and active early warning of patient individual drug inventory, effectively solves the problem of drug discontinuation or waste caused by traditional reliance on human memory, provides objective medication data support for doctors, and thus improves medication safety, treatment continuity and medical service quality.

A medication adherence device includes a camera unit comprising a camera. A medication unit can be physically docked and undocked with the camera unit, wherein the medication unit comprises a plurality of medication compartments for organizing medications corresponding to tablets according to a prescribed medication schedule. The medication unit includes one or more light emitting diodes (LEDs) associated with the respective medication compartments and the medication compartments are within a field of view of the camera. An interface unit coupled to control the one or more LEDs.